ストックスクリーナーアプリを入手
2.415
3.67%
0.085
前日終値:
$2.33
開ける：
$2.34
24時間の取引高:
1.06M
Relative Volume:
0.30
時価総額：
$289.97M
収益：
$6.65M
当期純損益:
$-136.32M
株価収益率:
-2.1042
EPS:
-1.1477
ネットキャッシュフロー:
$-112.04M
1週間 パフォーマンス:
-7.80%
1か月 パフォーマンス:
+0.23%
6か月 パフォーマンス:
+49.11%
1年 パフォーマンス:
+110.05%
1日の値動き範囲:
$2.23
$2.42
1週間の範囲:
$2.23
$2.70
52週間の値動き範囲:
$0.9335
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
名前
Fate Therapeutics Inc
セクター
電話
858.875.1803
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.42 | 293.56M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
548.34 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
829.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,009.75 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.18 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.71 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-19 | 再開されました | Jefferies | Buy |
| 2025-10-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-11-18 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-06-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Wells Fargo | Equal Weight |
| 2023-01-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-01-06 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | ダウングレード | Stifel | Buy → Hold |
| 2023-01-06 | ダウングレード | Truist | Buy → Hold |
| 2023-01-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 開始されました | Goldman | Sell |
| 2022-11-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-08-18 | 再開されました | Wells Fargo | Overweight |
| 2022-07-28 | 開始されました | Needham | Hold |
| 2022-07-11 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-11 | 再開されました | BMO Capital Markets | Market Perform |
| 2021-12-15 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-11-09 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-07 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Jefferies | Buy |
| 2021-02-26 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-02-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-01-27 | 再開されました | H.C. Wainwright | Neutral |
| 2020-05-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-09 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 繰り返されました | Mizuho | Buy |
| 2019-12-09 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-06 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 開始されました | Stifel | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-07-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-06-07 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Buy |
| 2019-05-24 | 再開されました | Citigroup | Buy |
| 2019-03-28 | 開始されました | SVB Leerink | Outperform |
| 2019-01-03 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 開始されました | Jefferies | Buy |
| 2018-08-01 | 開始されました | Citigroup | Buy |
| 2018-03-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
すべてを表示
Fate Therapeutics Inc (FATE) 最新ニュース
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et
Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com
Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative
Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan
Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE - MarketBeat
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Fate Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Fate Therapeutics, Inc. (FATE) Latest Stock News & Headlines - Yahoo! Finance Canada
Fate Therapeutics Reports Q2 2026 10-Q Filing Highlighting iPSC Pipeline and Key Risks - Kalkine Media
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com - Investing.com Australia
Fate Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises - TradingView
Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss - Quiver Quantitative
Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M - TradingView
Fate Therapeutics Inc expected to post a loss of 27 cents a shareEarnings Preview - tradingview.com
Fate Therapeutics (FATE) Short Interest & Short Float | Updated Aug 2026 $FATE - MarketBeat
Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Don't Ignore The Insider Selling In Fate Therapeutics - webull.com
Fate Therapeutics (NASDAQ: FATE) CLO sells 38,800 shares to cover taxes - Stock Titan
Fate Therapeutics (FATE) CEO sells 43,947 shares to cover RSU tax - Stock Titan
FATE (FATE) insider files to sell 38,800 common shares on NASDAQ - Stock Titan
FATE (FATE) holder discloses 43,947-share potential sale and prior trade - Stock Titan
Fate Therapeutics (FATE) to Release Quarterly Earnings on Tuesday - MarketBeat
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)August 3, 2026 - marketscreener.com
FATE Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Fate Therapeutics (FATE) Advances 3% to $2.58, Testing Key Resistance at $2.71Value Factor - vinanet.vn
FATE Q1 2026 Earnings: EPS Beats Estimates by 8.96%, Shares Slip 2.39%Profit Growth Outlook - Vinanet
FATE Q1 2026 Earnings: Narrower Loss Beats Estimates by 8.96%, Yet Shares Slip 3%Short-Term Outlook - Vinanet
Fate Therapeutics (FATE) Shows Modest Gain Amid Biotech Sector RotationMA Crossover - vinanet.vn
Cash flow from operating activities of Fate Therapeutics, Inc. – HAM:F6T - TradingView
FATE|Fate Therapeutics Inc|Price:2.615|Chg%:+0.045 - TradingKey
Fate Therapeutics Inc (FATE) Cash Flow - TradingKey
Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Inc (FATE) 財務データ
収益
当期純利益
現金流量
EPS
1.38%
1.04%
大文字化:
|
ボリューム (24 時間):